Translational Utility of Liquid Biopsies in Thyroid Cancer Management

Wijewardene, Ayanthi; Chehade, Marthe; Gild, Matti; Clifton‐Bligh, Roderick; Bullock, Martyn

doi:10.3390/cancers13143443

Cited by 16 publications

(4 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Tg has limited clinical value in postoperative TC follow-up for poorly differentiated thyroid cancer [ 151 ]. CT levels can be affected by other diseases such as chronic renal failure and parathyroid disease [ 152 ]. Imaging examinations may have adverse effects on the human body due to repeated radiation exposure.…”

Section: Future Perspectivesmentioning

confidence: 99%

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review

Wang,

Zheng,

Lei

2023

IJMS

View full text Add to dashboard Cite

Thyroid cancer has become more common in recent years all around the world. Many issues still need to be urgently addressed in the diagnosis, treatment, and prognosis of thyroid cancer. Liquid biopsy (mainly circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating exosomes) may provide a novel and ideal approach to solve these issues, allows us to assess the features of diseases more comprehensively, and has a function in a variety of malignancies. Recently, liquid biopsy has been shown to be critical in thyroid cancer diagnosis, treatment, and prognosis in numerous previous studies. In this review, by testing CTCs, ctDNA, and exosomes, we focus on the possible clinical role of liquid biopsy in thyroid cancer, including diagnostic and prognostic biomarkers and response to therapy. We briefly review how liquid biopsy components have progressed in thyroid cancer by consulting the existing public information. We also discuss the clinical potential of liquid biopsy in thyroid cancer and provide a reference for liquid biopsy research. Liquid biopsy has the potential to be a useful tool in the early detection, monitoring, or prediction of response to therapies and prognosis in thyroid cancer, with promising clinical applications.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review

Wang,

Zheng,

Lei

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Liquid biopsy provides a non- or minimally-invasive approach to the diagnostic work-up, risk stratification, and monitoring of patients who are suspected of having or are on treatment for FTC [ 212 ]. Liquid biopsies sample blood, saliva, or urine to look for circulating tumor cells, cell-free DNA, or extracellular vesicles (exosomes) that are released from the tumor [ 199 , 213 , 214 ]. Liquid biopsy is useful for differentiating FA from FTC, assessing the TME, early identification of metastases, and a de-differentiated FTC [ 163 , 199 , 212 , 215 , 216 ].…”

Section: Multi-omics Of Follicular Carcinoma and Other Thyroid Tumorsmentioning

confidence: 99%

Multi-Omics and Management of Follicular Carcinoma of the Thyroid

et al. 2023

View full text Add to dashboard Cite

Follicular thyroid carcinoma (FTC) is the second most common cancer of the thyroid gland, accounting for up to 20% of all primary malignant tumors in iodine-replete areas. The diagnostic work-up, staging, risk stratification, management, and follow-up strategies in patients who have FTC are modeled after those of papillary thyroid carcinoma (PTC), even though FTC is more aggressive. FTC has a greater propensity for haematogenous metastasis than PTC. Furthermore, FTC is a phenotypically and genotypically heterogeneous disease. The diagnosis and identification of markers of an aggressive FTC depend on the expertise and thoroughness of pathologists during histopathological analysis. An untreated or metastatic FTC is likely to de-differentiate and become poorly differentiated or undifferentiated and resistant to standard treatment. While thyroid lobectomy is adequate for the treatment of selected patients who have low-risk FTC, it is not advisable for patients whose tumor is larger than 4 cm in diameter or has extensive extra-thyroidal extension. Lobectomy is also not adequate for tumors that have aggressive mutations. Although the prognosis for over 80% of PTC and FTC is good, nearly 20% of the tumors behave aggressively. The introduction of radiomics, pathomics, genomics, transcriptomics, metabolomics, and liquid biopsy have led to improvements in the understanding of tumorigenesis, progression, treatment response, and prognostication of thyroid cancer. The article reviews the challenges that are encountered during the diagnostic work-up, staging, risk stratification, management, and follow-up of patients who have FTC. How the application of multi-omics can strengthen decision-making during the management of follicular carcinoma is also discussed.

show abstract

“…Nonetheless, mishaps in the detection of alternative biomarkers, insufficient tissue obtention, or incompatibility with long-term monitoring, among other limitations still exist ( 5 ). Compared with solid biopsy, LB is a more comprehensive diagnostic test that uses blood, urine ( 67 ), saliva, and other biological fluids ( 68 , 69 ). After the sampling circulating tumor nucleic acids and cells are extracted and further analyzed ( 68 , 70 ).…”

Section: Liquid Biopsy In Breast Cancermentioning

confidence: 99%

Potential utility of miRNAs for liquid biopsy in breast cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer (BC) remains the most prevalent malignancy due to its incidence rate, recurrence, and metastasis in women. Conventional strategies of cancer detection– mammography and tissue biopsy lack the capacity to detect the complete cancer genomic landscape. Besides, they often give false- positive or negative results. The presence of this and other disadvantages such as invasiveness, high-cost, and side effects necessitates developing new strategies to overcome the BC burden. Liquid biopsy (LB) has been brought to the fore owing to its early detection, screening, prognosis, simplicity of the technique, and efficient monitoring. Remarkably, microRNAs (miRNAs)– gene expression regulators seem to play a major role as biomarkers detected in the samples of LB. Particularly, miR-21 and miR-155 among other possible candidates seem to serve as favorable biomarkers in the diagnosis and prognosis of BC. Hence, this review will assess the potential utility of miRNAs as biomarkers and will highlight certain promising candidates for the LB approach in the diagnosis and management of BC that may optimize the patient outcome.

show abstract

Translational Utility of Liquid Biopsies in Thyroid Cancer Management

Cited by 16 publications

References 104 publications

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review

Multi-Omics and Management of Follicular Carcinoma of the Thyroid

Potential utility of miRNAs for liquid biopsy in breast cancer

Contact Info

Product

Resources

About